bioRxivCancer Biology
Single-PanIN-seq Unveils that ARID1A Deficiency Promotes Pancreatic Tumorigenesis by Attenuating KRAS Induced Senescence
Abstract
ARID1A is one of the most frequently mutated epigenetic regulators in a wide spectrum of cancers. Recent studies have shown that ARID1A deficiency induces global changes in the epigenetic landscape of enhancers and promoters. These broad and complex effects make it challenging to identify the driving mechanisms of ARID1A deficiency in promoting cancer progression. Here we identified the anti-senescence effect of ARID1A deficiency in the progression of pancreatic intraepithelial neoplasia (PanIN) by profiling the transcriptome of individual PanINs in the mouse model. Interestingly, we found that ARID1A deficiency upregulates the expression of Aldehyde dehydrogenase ALDH1A1, which plays an essential role in attenuating the senescence induced by oncogenic KRAS. Despite that ALDH proteins have been commonly used as cancer stem cell markers, their effect in promoting attenuation of senescence is not known before. Therefore, ALDH proteins could be considered a potential adjuvant drug target in treating pancreatic cancer.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis
S. Ferri-Borgogno, S. Barui, … S. Gupta·bioRxiv·Nov 8, 2019
- Aryl hydrocarbon receptor knockout accelerates PanIN formation and fibro-inflammation in a mutant Kras-driven pancreatic cancer model
M. Walcheck, P. Schwartz, … S. Ronnekleiv-Kelly·bioRxiv·Feb 1, 2023
- Prevention and reversion of pancreatic tumorigenesis through a differentiation-based mechanism
N. M. Krah, D. Yugawa, … L. C. Murtaugh·bioRxiv·Nov 19, 2017
- IFNA pathway drives the more aggressive phenotype of KRASG12D-mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation
D. G. Duda, K. Inoue, … N. Bardeesy·bioRxiv·Jun 29, 2022
- Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity
S. K. Fey, A. K. Najumudeen, … O. J. Sansom·bioRxiv·Aug 29, 2023
- Loss of Activating Transcription Factor 3 prevents KRAS-mediated pancreatic cancer